Analysis of Placental Tissue in Fabry Disease With and Without Enzyme Replacement Therapy
Accepted 3 February 2010. published online 02 March 2010.
Abstract
There are only a few reports on the histology of placental tissue of pregnancies from mothers with Fabry disease. Fabry disease is a lysosomal disorder caused by α-galactosidase A deficiency. Extensive glycosphingolipid (GSL) accumulation in fetal and maternal placenta tissue obtained from a Fabry mother and her affected male newborn has previously been reported. Here we report the evaluation of placenta tissue of two pregnancies in Fabry mothers, one of an unaffected male newborn (placenta A) and one of an affected female newborn (placenta B). The mother of the female affected offspring was treated with recombinant α-galactosidase A (enzyme replacement therapy, ERT) during the pregnancy (placenta B). Storage material was only detected in smooth muscle cells of the umbilical cord of placenta B. No accumulation was seen in both placentae. Combing these results with the outcome in two earlier described placentae, a heterogeneous picture emerges. This may be due to differences in disease severity in the mothers or severity of disease in their offspring. In addition, a possible effect of ERT on placental GSL accumulation could also explain lack of GSL storage in placenta B.
aDepartment of Paediatrics, Emma Children's Hospital, Amsterdam, The Netherlands
bDepartment of Internal Medicine, Division of Endocrinology and Metabolism, Amsterdam, The Netherlands
cDepartment of Pathology, All at the Academic Medical Center, Amsterdam, The Netherlands
Corresponding author. Department of Internal Medicine (F5-166), Division of Endocrinology and Metabolism, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. Tel.: +31 205668890.